Patient-specific Boolean models of signalling networks guide personalised treatments

Prostate cancer is the second most occurring cancer in men worldwide. To better understand the mechanisms of tumorigenesis and possible treatment responses, we developed a mathematical model of prostate cancer which considers the major signalling pathways known to be deregulated. We personalised this Boolean model to molecular data to reflect the heterogeneity and specific response to perturbations of cancer patients. A total of 488 prostate samples were used to build patient-specific models and compared to available clinical data. Additionally, eight prostate cell line-specific models were built to validate our approach with dose-response data of several drugs. The effects of single and combined drugs were tested in these models under different growth conditions. We identified 15 actionable points of interventions in one cell line-specific model whose inactivation hinders tumorigenesis. To validate these results, we tested nine small molecule inhibitors of five of those putative targets and found a dose-dependent effect on four of them, notably those targeting HSP90 and PI3K. These results highlight the predictive power of our personalised Boolean models and illustrate how they can be used for precision oncology.Read more…

Prostate cancer is the second most occurring cancer in men worldwide. To better understand the mechanisms of tumorigenesis and possible treatment responses, we developed a mathematical model of prostate cancer which considers the major signalling pathways known to be deregulated. We personalised this Boolean model to molecular data to reflect the heterogeneity and specific response to perturbations of cancer patients. A total of 488 prostate samples were used to build patient-specific models and compared to available clinical data. Additionally, eight prostate cell line-specific models were built to validate our approach with dose-response data of several drugs. The effects of single and combined drugs were tested in these models under different growth conditions. We identified 15 actionable points of interventions in one cell line-specific model whose inactivation hinders tumorigenesis. To validate these results, we tested nine small molecule inhibitors of five of those putative targets and found a dose-dependent effect on four of them, notably those targeting HSP90 and PI3K. These results highlight the predictive power of our personalised Boolean models and illustrate how they can be used for precision oncology.Read more…


Type Path Last modified Size Actions
Dockerfile 1 year, 11 months ago 271.0B
elife-72626.references.bib 1 year, 11 months ago 38.8KiB
elife-72626.rmd 1 year, 11 months ago 91.7KiB
elife-72626.xml 1 year, 11 months ago 411.6KiB
elife-72626.xml.media 1 year, 11 months ago 37.6MiB
elife-72626_clean.xml 1 year, 11 months ago 477.1KiB
elife-72626_clean2.xml 1 year, 11 months ago 411.5KiB
elife-72626_v0.rmd 1 year, 11 months ago 91.7KiB
elife-72626_v1.rmd Main 1 year, 11 months ago 133.9KiB
elife-72626_v2.rmd 1 year, 11 months ago 138.5KiB
index.html 1 year, 11 months ago 651.3KiB
index.html.media 1 year, 11 months ago 3.1MiB
upload-2098-elife-72626_v1.rmd 1 year, 11 months ago 133.9KiB